CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone310-826-5648
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$250,000.00
Profitability
Miscellaneous
Employees6
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
CytRx (NASDAQ:CYTR) Frequently Asked Questions
What is CytRx's stock symbol?
CytRx trades on the NASDAQ under the ticker symbol "CYTR."
When did CytRx's stock split? How did CytRx's stock split work?
CytRx shares reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.
How were CytRx's earnings last quarter?
CytRx Co. (NASDAQ:CYTR) issued its quarterly earnings data on Monday, August, 6th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.08. View CytRx's Earnings History.
When is CytRx's next earnings date?
What price target have analysts set for CYTR?
1 analysts have issued 12 month price objectives for CytRx's shares. Their predictions range from $5.00 to $5.00. On average, they anticipate CytRx's share price to reach $5.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price. View Analyst Price Targets for CytRx.
What is the consensus analysts' recommendation for CytRx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytRx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytRx.
What are Wall Street analysts saying about CytRx stock?
Here are some recent quotes from research analysts about CytRx stock:
- 1. According to Zacks Investment Research, "CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies. " (1/7/2019)
- 2. HC Wainwright analysts commented, "Our price target is based on a composite valuation assessment that ascribes: (1) $105M to the future royalty streams from sales of aldoxorubicin, to which we assign a 60% probability of success and 12% discount rate; and (2) $55M to the LADR portfolio of candidates, which includes the companion diagnostic platform." (11/5/2018)
Has CytRx been receiving favorable news coverage?
Media stories about CYTR stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytRx earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future.
Who are some of CytRx's key competitors?
Some companies that are related to CytRx include Aptose Biosciences (APTO), Idera Pharmaceuticals (IDRA), Cidara Therapeutics (CDTX), Pluristem Therapeutics (PSTI), Curis (CRIS), BioCardia (BCDA), Entera Bio (ENTX), Pharmacyte Biotech (PMCB), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL), Titan Pharmaceuticals (TTNP), TRACON Pharmaceuticals (TCON), aTyr Pharma (LIFE) and Outlook Therapeutics (OTLK).
What other stocks do shareholders of CytRx own?
Who are CytRx's key executives?
CytRx's management team includes the folowing people:
- Mr. Steven A. Kriegsman, Chairman & CEO (Age 77)
- Mr. John Y. Caloz, Chief Financial Officer (Age 67)
- Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 56)
- Mr. Eric L. Curtis M.B.A., Pres & COO (Age 50)
How do I buy shares of CytRx?
Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytRx's stock price today?
One share of CYTR stock can currently be purchased for approximately $0.55.
How big of a company is CytRx?
CytRx has a market capitalization of $18.50 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-12,710,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. CytRx employs 6 workers across the globe.
What is CytRx's official website?
How can I contact CytRx?
CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]
MarketBeat Community Rating for CytRx (NASDAQ CYTR)
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
